EMA committee recommends Yuviwel (navepegritide) for children with achondroplasia

Dette opslag vises på engelsk, indtil oversættelsen er opdateret.

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended authorising Yuviwel (navepegritide), a prodrug containing C-type natriuretic peptide, for children aged 2 years and older with genetically confirmed achondroplasia whose epiphyses (bone growth plates) are not closed. In a 52-week randomised, double-blind, placebo-controlled trial, it improved annualised growth velocity by 1.49 cm compared with placebo. The most common side effects were injection site reactions and hypertrichosis (abnormal hair growth). A CHMP opinion is followed by a European Commission decision.

Kilder

  1. 01Yuviwel: opinion on marketing authorisation(åbner kilden i en ny fane) European Medicines Agency
  2. 02Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026(åbner kilden i en ny fane) European Medicines Agency